This gap in real-world diagnostic accessibility, combined with the increasing sophistication of gene therapy (GMO) trials, presents unprecedented challenges for trial sponsors navigating the complex intersection of GMO regulations and CDx requirements within the European Union (EU). As these requirements become increasingly stringent, understanding the nuanced European regulatory landscape has become crucial for ensuring successful trial planning and execution.

This expert-led webinar delivers essential insights for biotech and specialty pharma companies planning GMO trials with CDx in the EU, as well as strategies for successful trial implementation. Through practical case studies and real-world examples, we will explore the intricate regulatory pathways and operational considerations that impact trial readiness and timeline management, with a focus on rare diseases and the unique challenges faced in neurological indications.

Key areas of focus include:

• A clear understanding of the latest EU regulatory requirements for conducting GMO trials with CDx.
• Strategic approaches to navigate complex European submission processes and ensure regulatory compliance.
• Key operational readiness factors that can impact trial execution, from site selection to logistics.
• Essential insights for US-based sponsors looking to successfully conduct GMO trials in Europe.

This webinar is designed for regulatory and clinical leaders who need to confidently navigate the evolving European regulatory landscape while ensuring smooth and efficient trial execution. Attendees will walk away with actionable strategies to streamline submissions, maintain compliance, and tackle operational hurdles in GMO trials with companion diagnostics—empowering them to drive successful outcomes in their gene therapy programs.